Protokoly_diagnostiki_i_lechenia_zabolevany

, % " ;B?, +6 "$& 75 % .

+ : 1 . 3 & " 1 ,5, 10 1 2-3 . 6 % &" & 50,0 100,0 " 5 10 V .

- $ 40-80 – 3 & . " 1-3 ." $, # , " , . $# @7$ – "& ( % 200 60040 " ); 3 + + 3 "$ 1-2 . 3 / 1 . 3 / ( & 5 .) " 6 &. & "$ 2 / / &200 5% $. & - 1-2 / . " - 7-10 .

" & :

1.20 ,

2.! 20 ,

3.*J 10 , 20 , 40 ,

4._ 20 ,

5.*? 100 ,

7.*' 5, 10 ,

8.*-, 3 40

9.*@ "& , 200 , %

10.3 + + 3

11. * " & , V 5, 10 20

" & & :

1. Drug treatment for hyperlipidaemias EBM Guidelines 22.4.2004

2.Cerebrovascular disease. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000

3.Aspirin for the primary prevention of cardiovascular events: recommendations and rationale/ Ann Intern Med 2002.

4.Cerebral arteriosclerosis. National institute of Neurological disorders and stroke (NINDS)

5.AHA|ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update.

6. " // . '.O. + .-6.: “)? B ! ”, 2001.-96 .

7.Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative aktovegin in age-associated memory impairment. Semlitsch Heribert V., Anderer Peter, Saletu Bernd, Hochmayer Ingrid. Neuropsychobiology 1990-91; 24:49-56; Sections of Clinical Psychophysiology Pharmacopsychatry.

8.Clinical Neurology. /D.Greenberg, M.Aminoff, R.Simon Lange Medical Book. 2002

* – , # (% % )

' & & : 10 .

(: '86 L

) : R - % , " " # Sarcoptes scabiei hominis, $# % " .

$ : ( " )

1.; "

2.+ % ( $)

3." ( " % )

4.) ( , " , )

5.L «" »-

* : " & (", & & ; ), " & , & -" , " " , .

:

1.;# & 3 " .

2.' % % , $# " " .

3.L " - $# , -

1 & . + ( ) "

5.% " " # " " .

? " :

1., " "- , # 3 ,( % " ).

2.+ " 3 , , # ( " ).

3. + " - " " ( " )

" & :

1.6

2.#

3.# "

" & & :

1. J % " " #

+ :

+ & & « » " . % % & " . % % & & & .

1. 5% « » , $" % , , . + & " , ,. ' " # " & " . L 8-12 " &. & " 7(" # " ).

2. '-&$ 3 &$ (20%- 10%- )# & $ % - 2 &10 1- 4- & " . ' 2- 3- & " " . ! & & & % :. < & " $# 3- ,$ % & . L 3 & "& & . @ %$ & "$ , " " 3-4 . J " .

3.33% ( ) 20% ( ) &. " " & . 6 & $ % " 5-7 , "$ " " # . L 6-8 && & & .

4.?3 & 3 & % $"

& , " .

5. @ , % , , ,(?-? ) 3 & , # %$ & . % & & & " " & " 10 .

" & :

1.'-& 3 & , & (20%- 10%- )

2.! & 33% ( ) 20% ( ) 50-100

" & & :

1.?3 & 3 , 152

2.5%

,- ! :

3 " : & $ & " 3 " % 10 % 1,5 ( 848 26.01.2004 . 6) )$# 3 ( ): % & ( 3 , ); " ; 3 .

/ , & :

1.Walker G.A., Johnstone P.W. Interventions for treating scabies. In: The Cochrane Library, Issue 3, 2001.

2.Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Veneral Disease (MSSVD). 2002 national guideline on the management of scabies. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Veneral Disease (MSSVD); 2002.

3.% " . " . ' .M. .! , '.+.6 .- 6., 6 , 1999.

4. ! " ' &-2005. J .

5.% " . " . M.!. < .

6.« " ». 6 6 ? . ! " , >.<.6 & .

* – , # (% % )

#

: 03-034

"$ &: "

: 6!

& ! : " , % , &(: H74.1 ? &

) : ) - & % %

.

" & :

1.; "

2.B " (I &)

3.; (II &)

4.' & & (III &)

5.(IV &)

6.(V &)

7.?3 " : , & 3 " ;

;

8.? " ( )

9.6

10.&$

" & :

1.*; V 5% 1

2.* 10

3.*/ V 1 (500 )

5.V 1 (100 )

6.+ & 10 ,

7.*7 V 0,18% 1

" & & :

,- ! : , $#"$, " " , " 3 .

/ , & :

1.< " .'., H$ '. ., ; . . 6 3. ' , N 2-2000, . 4647;

2.http://www.curaremed.ru/index.asp?rid=1846, ! "$# ;

3.&" '.;., $ ?.B., ; ?.<., K 6.+., / '.!. @. + " . ' , N 4-2000, . 5-10.

* – , # (% % ) .

> & % " & " , % & & 5

1 – ( 5 / ) 1- (1)

H % & ( " ),&.

% " , %$# " " " %$$.

$# 3 " :

) % " " " " V 300 ;

+ ;

B " # ;

" ;

' % & , " ,

" 3 " 3 ".

" & :

1.; 400

2.? & 5

3.; 5

" & & :

,- ! : 3 & "

/ , & :

1.Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000; 38: 2-19;

2.Wilt T, Ishani A, Stark G, MacDonald R, Milrow C, Lau J. Serenoa repena for benign prostatic hyperplasia. In: The cochrane Library, Issue 3, 2001;

3.Prodigy Guidance – Prostate – benign gyperplasia, 2002.

* – , # (% % ) .

# &

: 03-035

"$ &: "

: 6!

& ! : , " # .

(: J03

J03.9 "

) : ) ( ) - 3 " " & , " # , , % .

: < & , , # , .

" & :

1.&

2.# (6 )

Haemophilus influenzae, Moraxella catarrhalis Streptococcus pneumoniae (3), -" (4,5,6), ! (7), &

& & % ,

450 & " 7-10 . % 3 400 2-4 &.

" & :

1. * 200 , 500 ; 2,4% ; 80

2.*B 200 , 400

3._ 500

4. *7 250 , 500 ; & 250 /5

5.*/ 250 , 500

6.150 , 300

/ , & :

1.Prodigy Knowledge. Prodigy Guidance-Sore Throat Acute. 2004.

2.Institute For Clinical System Improvement. Health Care Guideline. Acute Pharyngitis. May 2005. 3.EBM Guideline. Sore Throat and Tonsillitis. 2004.

4.National Guideline Clearinghouse. Guideline. Sore Throat and Tonsillitis. December 2005. 5. National Guideline Clearinghouse. Guideline. Acute Pharyngitis. December 2005.

6.Scottish Intercollegiate Guidelines Network. National Clinical Guideline. Management of Sore Throat and Indications for Tonsillectomy. January 1999.

7.Alberta Medical Association. Guideline. The Diagnosis and Treatment of Acute Pharyngitis. November 2001.

8.American Society of Infection Diseases. A Practice Guideline. Diagnosis and Management of Group A Streptococcal Pharyngitis.1997.

9.University of Michigan Health System. Guidelines for Clinical Care. Pharyngitis. December 2000. 10.Advisory Committee. Guidelines & Protocols. Diagnosis and Management of Sore Throat. 2003. 11. American Society of Infection Diseases. Practice Guidelines for the Diagnosis and Management of Group A Streptococcal Pharyngitis.2002.

* – , # (% % ) .